Berman Tabacco represents the named plaintiff and the proposed class in this class action lawsuit brought under federal and state antitrust laws and state unfair trade practices laws alleging that defendant Teva and its affiliates, embarked on a nearly decade-long (and continuing) anticompetitive scheme to delay generic competition for QVAR, its blockbuster line of brand-name asthma inhalers. This action seeks to recover the overcharges sustained by end-payors for QVAR and QVAR Redihaler, and to enjoin further extensions to Teva’s unlawful monopoly.
